vs
Side-by-side financial comparison of InMed Pharmaceuticals Inc. (INM) and Pineapple Financial Inc. (PAPL). Click either name above to swap in a different company.
InMed Pharmaceuticals Inc. is the larger business by last-quarter revenue ($820.2K vs $707.3K, roughly 1.2× Pineapple Financial Inc.). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -2756.2%, a 2508.9% gap on every dollar of revenue. On growth, Pineapple Financial Inc. posted the faster year-over-year revenue change (-4.8% vs -26.2%). Over the past eight quarters, Pineapple Financial Inc.'s revenue compounded faster (-2.0% CAGR vs -16.4%).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
INM vs PAPL — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $820.2K | $707.3K |
| Net Profit | $-2.0M | $-19.5M |
| Gross Margin | 22.5% | 48.9% |
| Operating Margin | -247.3% | -2518.8% |
| Net Margin | -247.3% | -2756.2% |
| Revenue YoY | -26.2% | -4.8% |
| Net Profit YoY | 21.2% | -3174.1% |
| EPS (diluted) | $-0.51 | $-1.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $707.3K | ||
| Q4 25 | $820.2K | $721.7K | ||
| Q3 25 | $1.1M | $730.5K | ||
| Q2 25 | $1.3M | $746.9K | ||
| Q1 25 | $1.3M | $743.3K | ||
| Q4 24 | $1.1M | $766.1K | ||
| Q3 24 | $1.3M | $598.3K | ||
| Q2 24 | $1.3M | $736.4K |
| Q1 26 | — | $-19.5M | ||
| Q4 25 | $-2.0M | $-6.4M | ||
| Q3 25 | $-1.7M | $-1.8M | ||
| Q2 25 | $-1.8M | $-557.7K | ||
| Q1 25 | $-2.1M | $-595.4K | ||
| Q4 24 | $-2.6M | $-656.9K | ||
| Q3 24 | $-1.7M | $-1.7M | ||
| Q2 24 | $-1.9M | $-848.6K |
| Q1 26 | — | 48.9% | ||
| Q4 25 | 22.5% | 49.6% | ||
| Q3 25 | 36.0% | 27.8% | ||
| Q2 25 | 44.2% | 67.6% | ||
| Q1 25 | 13.9% | 43.4% | ||
| Q4 24 | 41.5% | 45.9% | ||
| Q3 24 | 39.0% | 43.2% | ||
| Q2 24 | 36.3% | 44.2% |
| Q1 26 | — | -2518.8% | ||
| Q4 25 | -247.3% | -909.1% | ||
| Q3 25 | -154.2% | -131.3% | ||
| Q2 25 | -137.1% | -93.3% | ||
| Q1 25 | -168.1% | -80.6% | ||
| Q4 24 | -231.6% | -90.5% | ||
| Q3 24 | -132.7% | -232.8% | ||
| Q2 24 | -150.5% | -121.7% |
| Q1 26 | — | -2756.2% | ||
| Q4 25 | -247.3% | -891.6% | ||
| Q3 25 | -154.2% | -250.3% | ||
| Q2 25 | -137.1% | -74.7% | ||
| Q1 25 | -168.1% | -80.1% | ||
| Q4 24 | -231.6% | -85.7% | ||
| Q3 24 | -132.7% | -283.9% | ||
| Q2 24 | -151.0% | -115.2% |
| Q1 26 | — | $-1.21 | ||
| Q4 25 | $-0.51 | $-4.79 | ||
| Q3 25 | $-0.44 | $-0.93 | ||
| Q2 25 | $-0.07 | $-0.05 | ||
| Q1 25 | $-1.94 | $-1.73 | ||
| Q4 24 | $-3.64 | $-2.60 | ||
| Q3 24 | $-2.71 | $-11.10 | ||
| Q2 24 | $2.39 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.6M | $27.1M |
| Total Assets | $11.2M | $48.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $7.0M | — | ||
| Q3 25 | $9.4M | — | ||
| Q2 25 | $11.1M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $5.6M | — | ||
| Q2 24 | $6.6M | — |
| Q1 26 | — | $27.1M | ||
| Q4 25 | $9.6M | $-5.5M | ||
| Q3 25 | $11.6M | $906.7K | ||
| Q2 25 | $13.4M | $842.6K | ||
| Q1 25 | $7.0M | $739.7K | ||
| Q4 24 | $6.2M | $1.3M | ||
| Q3 24 | $8.4M | $1.3M | ||
| Q2 24 | $9.2M | $2.0M |
| Q1 26 | — | $48.9M | ||
| Q4 25 | $11.2M | $10.6M | ||
| Q3 25 | $13.4M | $5.4M | ||
| Q2 25 | $15.6M | $4.7M | ||
| Q1 25 | $9.3M | $4.0M | ||
| Q4 24 | $8.5M | $4.1M | ||
| Q3 24 | $10.5M | $4.1M | ||
| Q2 24 | $11.8M | $4.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $-3.3M |
| Free Cash FlowOCF − Capex | — | $-3.3M |
| FCF MarginFCF / Revenue | — | -462.7% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-3.3M | ||
| Q4 25 | $-2.4M | $-489.7K | ||
| Q3 25 | $-1.6M | $-507.6K | ||
| Q2 25 | $-1.8M | $397.0K | ||
| Q1 25 | $-1.7M | $-172.6K | ||
| Q4 24 | $-2.5M | $-663.6K | ||
| Q3 24 | $-1.8M | $-264.7K | ||
| Q2 24 | $-1.0M | $123.0K |
| Q1 26 | — | $-3.3M | ||
| Q4 25 | — | $-491.7K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-264.7K | ||
| Q2 24 | — | $122.7K |
| Q1 26 | — | -462.7% | ||
| Q4 25 | — | -68.1% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -44.2% | ||
| Q2 24 | — | 16.7% |
| Q1 26 | — | 0.0% | ||
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
